Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: An open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

The Lancet Oncology

Volumn 15, Issue 9, 2014, Pages 1007-1018

  Iveson, Timothy ^a   Donehower, Ross C ^b   Davidenko, Irina ^c   Tjulandin, Sergey ^d   Deptala, Andrzej ^e   Harrison, Mark ^f   Nirni, Somanath ^g   Lakshmaiah, Kuntegowdanahalli ^h   Thomas, Anne ⁱ   Jiang, Yizhou ^j   Zhu, Min ^j   Tang, Rui ^j   Anderson, Abraham ^j   Dubey, Sarita ^j   Oliner, Kelly S ^j   Loh, Elwyn ^j  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c State Institution of Public Health Regional Clinical Oncology Dispensary   (Russian Federation)

^d N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

^f MOUNT VERNON HOSPITAL   (United Kingdom)

^g Indo American Cancer Institute and Research Centre   (India)

^h KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

ⁱ UNIVERSITY OF LEICESTER   (United Kingdom)

^j AMGEN INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; PLACEBO; RILOTUMUMAB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA; FATIGUE; FEMALE; FEVER; GENE; GENE DOSAGE; HAND FOOT SYNDROME; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INCIDENCE; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MET GENE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VOMITING; ADENOCARCINOMA; AGED; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; LOWER ESOPHAGUS SPHINCTER; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR INVASION;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CONFIDENCE INTERVALS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84905028489     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70023-3     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
3. Kang H, Kauh JS Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard?. Curr Treat Options Oncol 2011, 12:96-106.
4. Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697. for the ToGA Trial Investigators.
5. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012, 12:89-103.
6. Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999, 85:1894-1902.
7. Taniguchi K, Yonemura Y, Nojima N, et al. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 1998, 82:2112-2122.
8. Wu CW, Li AF, Chi CW, et al. Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep 1998, 5:817-822.
9. Janjigian YY, Tang LH, Coit DG, et al. MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev 2011, 20:1021-1027.
10. Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011, 29:4803-4810.
11. Drebber U, Baldus SE, Nolden B, et al. The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep 2008, 19:1477-1483.
12. Yu S, Yu Y, Zhao N, Cui J, Li W, Liu T c-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis. PLoS One 2013, 8:e79137.
13. Taniguchi T, Kitamura M, Arai K, et al. Increase in the circulating level of hepatocyte growth factor in gastric cancer patients. Br J Cancer 1997, 75:673-677.
14. Han SU, Lee JH, Kim WH, Cho YK, Kim MW Significant correlation between serum level of hepatocyte growth factor and progression of gastric carcinoma. World J Surg 1999, 23:1176-1180.
15. Beppu K, Uchiyama A, Morisaki T, et al. Elevation of serum hepatocyte growth factor concentration in patients with gastric cancer is mediated by production from tumor tissue. Anticancer Res 2000, 20:1263-1267.
16. Tanaka K, Miki C, Wakuda R, Kobayashi M, Tonouchi H, Kusunoki M Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma. Scand J Gastroenterol 2004, 39:754-760.
17. Jun HT, Sun J, Rex K, et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 2007, 13:6735-6742.
18. Zhang YW, Su Y, Lanning N, et al. Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 2005, 24:101-106.
19. Cao B, Su Y, Oskarsson M, et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci USA 2001, 98:7443-7448.
20. Gao CF, Xie Q, Zhang YW, et al. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor: c-Met-driven models of leiomyosarcoma. Mol Cancer Ther 2009, 8:2803-2810.
21. Wen PY, Schiff D, Cloughesy TF, et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol 2011, 13:437-446.
22. Gordon MS, Sweeney CS, Mendelson DS, et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 2010, 16:699-710.
23. Rosen PJ, Sweeney CJ, Park DJ, et al. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res 2010, 16:2677-2687.
24. Oliner KS, Tang R, Anderson A, et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. Proc Am Soc Clin Oncol 2012, 30(suppl). abstr 4005.
25. Knudsen BS, Zhao P, Resau J, et al. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol 2009, 17:57-67.
26. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358:36-46.
27. Lin DY, Wei LJ, Ying Z Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 1993, 80:557-572.
28. Ocvirk J, Reberšek M, Skof E, Hlebanja Z, Boc M Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer. Am J Clin Oncol 2012, 35:237-241.
29. Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013, 31:4105-4114.
30. Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013, 14:55-63.
31. Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci 1998, 111:237-247.
32. Gisleskog PO, Lu JF, Perez-Ruixo JJ, Magnusson MO, Zhu M A mechanistic model to characterize binding dynamics of AMG 102 to HGF ligands in cancer patients. Clin Pharm Ther 2010, 87(suppl 1):S83.
33. Zhu M, Doshi S, Gisleskog PO, et al. Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients. J Pharm Sci 2014, 103:328-336.
34. Zhu M, Tang R, Doshi S, et al. Exposure-response (E-R) analysis of rilotumumab (R, AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer. Proc Am Soc Clin Oncol 2012, 30(suppl). abstr 2535.